GlassScriptPhysician profile
Jeffrey A Hansen
NPI 1932199981
$1,645.84
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $136 · 2021: $19.91 · 2022: $346 · 2023: $504 · 2024: $16.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $222.37 | 2019-2020 | |
| Exact Sciences Corporation | $122.94 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $115.05 | 2020-2024 | Rexulti, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $112.29 | 2022-2023 | |
| Novo Nordisk INC | $91.00 | 2019-2023 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $88.99 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $87.85 | 2019-2023 | Spravato |
| Vanda Pharmaceuticals INC. | $83.69 | 2022-2023 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $80.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.85 | 2019-2020 | |
| Abbvie INC. | $65.05 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.38 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $58.60 | 2019-2020 | |
| Pfizer INC. | $44.23 | 2020-2023 | |
| Glaxosmithkline, LLC. | $41.76 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $35.54 | 2019-2022 | |
| Lilly USA, LLC | $28.63 | 2019-2023 | Mounjaro |
| Corium, LLC | $26.00 | 2023 | Azstarys |
| Allergan, INC. | $25.06 | 2019 | |
| Astellas Pharma US INC | $23.11 | 2019-2020 | |
| Antares Pharma, INC. | $19.97 | 2023 | Xyosted, Nocdurna, Tlando |
| Regeneron Healthcare Solutions, INC. | $19.91 | 2021 | |
| Abbott Laboratories | $17.22 | 2023 | Eterna |
| Halozyme INC | $16.68 | 2023 | |
| Avanir Pharmaceuticals, INC. | $16.32 | 2019 | |
| Lucid Diagnostics INC. | $15.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.54 | 2019 | |
| Amarin Pharma, INC. | $13.30 | 2020 | |
| Gilead Sciences, INC. | $12.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.